Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-622 in healthy participants
NCT06650761Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CDX-622 in asthma and allergic disease (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Safety as assessed by Toxicity Grading Scale and CTCAE v5.0 at Day 127. Started Nov 2024; status: completed.
02
Drugs
CDX-622
03
Conditions
asthmaallergic disease
Beyond the preview
Go deeper on NCT06650761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650761.